Oppenheimer cuts Spruce Biosciences shares target cut to $4 on trial results By Investing.com
© Reuters. On Thursday, Oppenheimer adjusted its outlook on Spruce Biosciences, Inc. (NASDAQ:SPRB), reducing the price target to $4 for ...
Thursday, March 6, 2025
Tag: Spruce
RECOMMENDED
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.